Clinical Study Of Yiqi Jiedu Tongluo Decoction In Preventing Oxaliplatin-induced Peripheral Neuropathy In Patients With Colorectal Cancer

ObjectiveTo observe the efficacy and safety of Yiqi Jiedu Tongluo Decoction in preventing colorectal cancer(qi deficiency and blood stasis syndrome)patients with peripheral neuropathy caused by chemotherapy with oxaliplatin regimen.MethodA total of 64 patients with colorectal cancer(qi deficiency and blood stasis syndrome)who were hospitalized in the Department of Oncology of Integrated Chinese and Western Medicine of the First Affiliated Hospital of Anhui Medical University and met the inclusion criteria were collected from March 2019 to October 2020.They were randomly divided into a test group of 32 cases and a control group of 32 cases.The test group was given Yiqi Jiedu Tongluo Decoction from the first day of XELOX regimen(capecitabine + oxaliplatin)chemotherapy.The control group only received XELOX chemotherapy.21 days were used as a treatment cycle for a total of 6 treatment cycles.After the second cycle,the fourth cycle,and the sixth cycle of treatment,the incidence,classification,safety indicators and the efficacy of TCM syndromes of the two groups of patients were compared;Before treatment and after the 6th cycle of treatment,the KPS scores of the two groups were compared.Use SPSS 25.0 software to carry on the statistical analysis to the above-mentioned data.Results1.There was no statistically significant difference between the two groups of patients in terms of age,gender,tumor origin,tumor stage,and cumulative dose of oxaliplatin(P>0.05).2.Comparison of the incidence of peripheral neurotoxicity between the two groups of patients: After the second cycle of treatment,there was no significant difference in the incidence of peripheral neurotoxicity between the two groups of patients(P>0.05);the fourth cycle,the sixth cycle after treatment,the difference in the incidence of peripheral neurotoxicity between the two groups of patients was statistically significant(P<0.05),and the incidence of peripheral neurotoxicity in the test group was lower than that in the control group.3.Comparison of peripheral neurotoxicity classification of the two groups of patients: After the second cycle of treatment,the comparison of the peripheral neurotoxicity classification of the two groups of patients was not statistically significant(P>0.05);after the fourth cycle,the sixth cycle treatment Compared with the classification of peripheral neurotoxicity between the two groups,the difference was statistically significant(P<0.05),and the incidence of grade II and grade III peripheral neurotoxicity in the test group was lower than that in the control group.4.Comparison of safety factors between the two groups of patients:(1)Comparison of the two groups of patients in terms of leukopenia and neutropenia: After the second cycle of treatment,the differences in the above factors were not statistically significant(P>0.05);After the fourth cycle,and the sixth cycle of treatment,the differences in the above factors were statistically significant(P<0.05),and the incidence of grade II and grade III leukopenia and neutropenia in the test group were lower than those in the control group.(2)Comparison of the two groups of patients in terms of thrombocytopenia,hemoglobin decrease,alanine aminotransferase increase,and serum creatinine increase: After the second cycle,the fourth cycle,and the sixth cycle,there was no statistically significant difference in the above factors(P>0.05).5.Comparison of the efficacy of TCM syndromes between the two groups of patients: after the second cycle,the fourth cycle,and the sixth cycle,the differences were statistically significant(P<0.05),and the efficacy of TCM syndromes in the test group was better than the control group.6.Comparison of the quality of life of the two groups of patients:(1)There was no statistically significant difference in the KPS scores of the two groups of patients before treatment(P>0.05).(2)After the sixth cycle of treatment,the difference in KPS scores between the two groups was statistically significant(P<0.05),and the test group was better than the control group.Conclusions1.Yiqi Jiedu Tongluo Decoction can reduce the incidence and grade of peripheral neuropathy caused by oxaliplatin chemotherapy in patients with colorectal cancer(qi deficiency and blood stasis type).2.Yiqi Jiedu Tongluo Decoction has a certain effect in improving patients’ TCM syndromes and the quality of life of patients,and it has reliable safety.